Mirjam Zeisel
  • E-mail :[email]
  • Phone : +33 3 68 85 37 03
  • Location : Strasbourg, France
Last update 2014-02-12 14:13:58.43

Mirjam Zeisel PhD, PharmD

Course and current status

Since 2009

Chargé de recherche (CR1), Inserm U1110 (ex U748), Strasbourg, France


Previous positions

  • “Poste Vert” Inserm, Inserm U748, Université Louis Pasteur, Faculté de Médecine, Strasbourg, France (2007-2008)
  • Postoc, Department of Medicine II, University of Freiburg, Germany (2005-2007)
  • PhD, Inserm U392, Université Louis Pasteur, Faculté de Pharmacie, Illkirch, France (2001-2004)


University degrees and diplomas

  • Habilitation à diriger des recherches (HDR), Université de Strasbourg, Strasbourg (2012)
  • PhD Immunology and Pharmacology, Université Louis Pasteur, Strasbourg (2004)
  • Master (DEA) Pharmacologie and pharmacochemistry, Université Louis Pasteur, Strasbourg (2001)
  • PharmD (Docteur en Pharmacie), Université Louis Pasteur, Strasbourg, France (2000)
  • Maîtrise des Sciences Biologiques et Médicales (MSBM), Université Louis Pasteur, Strasbourg (2000)

Scientific summary

Innate immunity and rheumatoid arthritis

During my PhD at Inserm U392, Strasbourg, in the team of Pr. D. WACHSMANN and Pr. J. SIBILIA, I studied the role of innate immunity in initiating or perpetuating joint inflammation and destruction during rheumatoid arthritis (RA) which is the most common inflammatory arthritis and is a major cause of disability. I investigated pathogen-host interactions at the cellular level and characterized intracellular signaling pathways leading to the release of pro-inflammatory cytokines and metalloproteases.

Virus-host interactions and liver diseases

Following my postdoc in Pr. T. BAUMERT’s team at the University Hospital in Freiburg, Germany, I pursued my research at Inserm U748 (now U1110) in Strasbourg, France. I currently co-lead a team with Pr. T. BAUMERT focussing on virus-host interactions and liver diseases (http://www.idf.inserm.fr/site/u748en/page.asp?page=4953).

HCV is a major cause of hepatitis in the world. The majority of HCV-infected individuals develop chronic infection, which may progress to liver cirrhosis and hepatocellular carcinoma. Preventive modalities are absent and the current antiviral treatment is limited by resistance, toxicity and high costs. Aiming at the identification of novel targets for preventive and therapeutic strategies against virus-induced liver disease, we characterized the molecular mechanisms of HCV entry and neutralization by antibodies. Our current research focuses on the characterization of virus host-interactions and the pathogenesis of viral infection with three main areas of research: (1) molecular mechanisms of viral entry, (2) host determinants of virus tropism and (3) virus-induced alteration of regulatory networks involved in liver disease and cancer.

Image d’exemple